

Tina Bhutani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1526778/publications.pdf>

Version: 2024-02-01

100
papers

3,578
citations

236925

25
h-index

149698

56
g-index

112
all docs

112
docs citations

112
times ranked

6001
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of diet on the gut microbiome and implications for human health. <i>Journal of Translational Medicine</i> , 2017, 15, 73.	4.4	1,714
2	The role of IL-17 in vitiligo: A review. <i>Autoimmunity Reviews</i> , 2016, 15, 397-404.	5.8	92
3	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2247-2259.	3.3	87
4	Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials. <i>Dermatology and Therapy</i> , 2016, 6, 111-124.	3.0	82
5	Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2370-2380.	2.9	77
6	Warfarin-Associated Nonuremic Calciphylaxis. <i>JAMA Dermatology</i> , 2017, 153, 309.	4.1	74
7	Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review. <i>Dermatology and Therapy</i> , 2017, 7, 349-364.	3.0	66
8	The impact of pediatric atopic dermatitis on families: A review. <i>Pediatric Dermatology</i> , 2019, 36, 66-71.	0.9	66
9	Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. <i>Dermatology and Therapy</i> , 2016, 6, 25-37.	3.0	62
10	Anti IL-17 in psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1185-1194.	3.0	61
11	Dupilumab Treatment for Generalized Prurigo Nodularis. <i>JAMA Dermatology</i> , 2019, 155, 118.	4.1	60
12	A review of dupilumab in the treatment of atopic diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2129-2139.	3.3	53
13	Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 713-718.	1.2	52
14	Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. <i>Dermatology and Therapy</i> , 2017, 7, 281-292.	3.0	49
15	The Role of the Nervous System in the Pathophysiology of Psoriasis: A Review of Cases of Psoriasis Remission or Improvement Following Denervation Injury. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 257-263.	6.7	47
16	Eczema as an adverse effect of anti-TNF \pm therapy in psoriasis and other Th1-mediated diseases: a review. <i>Journal of Dermatological Treatment</i> , 2017, 28, 237-241.	2.2	43
17	Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2013, 149, 717.	4.1	41
18	Biologic Treatments of Psoriasis: An Update for the Clinician. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 39-51.	3.2	40

#	ARTICLE	IF	CITATIONS
19	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. <i>Dermatology and Therapy</i> , 2020, 10, 339-349.	3.0	37
20	<p>Acrodermatitis continua of Hallopeau: clinical perspectives</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 65-72.	2.2	34
21	<p>Diagnosis and screening of patients with generalized pustular psoriasis</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 37-42.	2.2	31
22	Psoriasis risk factors and triggers. <i>Cutis</i> , 2018, 102, 18-20.	0.3	31
23	A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e79-e88.	1.2	30
24	The Patientâ€™s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. <i>Dermatology and Therapy</i> , 2016, 6, 307-313.	3.0	27
25	Review of the mechanism of action of coal tar in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 230-232.	2.2	27
26	Management of Pediatric Psoriasis. <i>Pediatric Annals</i> , 2012, 41, e1-7.	0.8	27
27	Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review. <i>Journal of Dermatological Treatment</i> , 2016, 27, 406-413.	2.2	26
28	The Role of IL-17 Cytokines in Psoriasis. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 409-418.	5.8	24
29	Recent Developments in Atopic Dermatitis. <i>Pediatrics</i> , 2018, 142, .	2.1	23
30	Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management. <i>Dermatology and Therapy</i> , 2021, 11, 769-797.	3.0	23
31	Obsessive-compulsive skin disorders: a novel classification based on degree of insight. <i>Journal of Dermatological Treatment</i> , 2017, 28, 342-346.	2.2	22
32	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. <i>JAAD Case Reports</i> , 2017, 3, 495-497.	0.8	21
33	Review of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 347-352.	2.2	21
34	Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. <i>Dermatology and Therapy</i> , 2019, 9, 511-523.	3.0	20
35	Recent advances in phototherapy for psoriasis. <i>F1000Research</i> , 2016, 5, 1684.	1.6	19
36	The Patientâ€™s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. <i>Dermatology and Therapy</i> , 2016, 6, 315-324.	3.0	18

#	ARTICLE	IF	CITATIONS
37	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019, 9, 407-420.	3.0	17
38	Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States. <i>JAMA Dermatology</i> , 2022, 158, 73.	4.1	17
39	A20 and ABIN1 Suppression of a Keratinocyte Inflammatory Program with a Shared Single-Cell Expression Signature in Diverse Human Rashes. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1264-1273.	0.7	16
40	Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 19-26.	0.7	15
41	Emerging therapies in psoriasis: a systematic review. <i>Cutis</i> , 2018, 101, 5-9.	0.3	15
42	Dupilumab in patients with chronic hepatitis B on concomitant entecavir. <i>JAAD Case Reports</i> , 2019, 5, 624-626.	0.8	14
43	Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability. <i>Psoriasis: Targets and Therapy</i> , 2016, Volume 6, 165-173.	2.2	12
44	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Dermatology and Therapy</i> , 2020, 10, 881-885.	3.0	12
45	Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. <i>Dermatology and Therapy</i> , 2021, 11, 799-831.	3.0	12
46	Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. <i>Cutis</i> , 2018, 101, 38;42;56.	0.3	12
47	Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability. <i>Psoriasis: Targets and Therapy</i> , 2016, Volume 6, 105-111.	2.2	11
48	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. <i>Frontiers in Immunology</i> , 2022, 13, 835760.	4.8	11
49	The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. <i>Dermatology and Therapy</i> , 2016, 6, 333-339.	3.0	10
50	Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 702-708.	2.2	10
51	Review of European registries for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 227-236.	2.2	10
52	Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1993-2000.	4.3	10
53	Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. <i>Dermatology and Therapy</i> , 2021, 11, 833-844.	3.0	10
54	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 333-344.	3.1	8

#	ARTICLE	IF	CITATIONS
55	<p>Home phototherapy for patients with vitiligo: challenges and solutions</p>. Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 451-459.	1.8	8
56	Efficacy of clobetasol spray: Factors beyond patient compliance. Journal of Dermatological Treatment, 2012, 23, 11-15.	2.2	7
57	Beyond the Booth. Dermatologic Clinics, 2020, 38, 157-163.	1.7	7
58	A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis. Practical Dermatology, 2010, 7, 31-35.	0.0	7
59	The Patientâ€™s Guide to Psoriasis Treatment. Part 3: Biologic Injectables. Dermatology and Therapy, 2016, 6, 325-331.	3.0	6
60	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 2018, 29, 467-474.	2.2	6
61	Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. Journal of Dermatological Treatment, 2019, 30, 519-521.	2.2	6
62	Sweet heart: A case of pregnancy-associated acute febrile neutrophilic dermatosis with myopericarditis. JAAD Case Reports, 2015, 1, 12-14.	0.8	5
63	Dupilumab for the treatment of severe photodermatitis. JAAD Case Reports, 2019, 5, 614-616.	0.8	5
64	Sleep, Immunological Memory, and Inflammatory Skin Disease. Dermatology, 2021, 237, 1035-1038.	2.1	5
65	Racial disparities in clinical trials of biologic treatments for psoriatic arthritis. Journal of the American Academy of Dermatology, 2022, 87, 910-912.	1.2	5
66	Perspectives on the Future Development of Mobile Applications for Dermatology Clinical Research. Dermatology and Therapy, 2021, 11, 1451-1456.	3.0	5
67	Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials. Dermatology and Therapy, 2021, 11, 1497-1520.	3.0	5
68	Common sources of skin care education: a cross-sectional study. International Journal of Dermatology, 2009, 48, 506-512.	1.0	4
69	Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study. Journal of the American Academy of Dermatology, 2016, 75, 1068-1071.	1.2	4
70	Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. International Journal of Women's Dermatology, 2016, 2, 62-64.	2.0	4
71	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Psoriasis: Targets and Therapy, 2017, Volume 7, 65-72.	2.2	4
72	Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 61-67.	0.7	4

#	ARTICLE	IF	CITATIONS
73	Sleep and the Gut Microbiome in Psoriasis: Clinical Implications for Disease Progression and the Development of Cardiometabolic Comorbidities. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 27-37.	0.7	4
74	Neuromodulation in Inflammatory Skin Disease. <i>Dermatology and Therapy</i> , 2018, 8, 1-4.	3.0	3
75	IL-23 Inhibitors for Psoriasis. <i>Current Dermatology Reports</i> , 2018, 7, 119-124.	2.1	3
76	Pharmacy costs of specialty medications for plaque psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 274-275.	1.2	3
77	Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. <i>International Journal of Women's Dermatology</i> , 2017, 3, S67-S69.	2.0	2
78	Lymphomatoid papulosis successfully managed with excimer laser maintenance therapy. <i>JAAD Case Reports</i> , 2020, 6, 495-497.	0.8	2
79	Phototherapy for Psoriasis: New Research and Insights. <i>Current Dermatology Reports</i> , 2021, 10, 16-20.	2.1	2
80	Dupilumab-Induced Facial Flushing After Alcohol Consumption. , 2021, 108, 106-107.		2
81	Do psoriasis patients engage in vigorous physical activity?. <i>Cutis</i> , 2018, 101, 198-200.	0.3	2
82	A Clinical Study Comparing the Efficacy of Halobetasol Propionate 0.05% Ointment Once Daily versus Twice Daily in Combination with Ammonium Lactate Lotion in the Treatment of Stable Plaque Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 2-8.	0.1	1
83	Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. <i>Journal of Dermatological Treatment</i> , 2013, 24, 348-350.	2.2	1
84	Vagus Nerve Stimulation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 54-58.	0.7	1
85	Palmoplantar Pustulosis in Electronic Cigarette Users: A Potential for Concern. <i>Dermatology</i> , 2019, 235, 525-526.	2.1	1
86	Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 82-85.	0.7	1
87	Psoriasis Vulgaris Successfully Treated with Goeckerman Treatment at Home: A Patient and Physician's Experience. <i>Dermatology and Therapy</i> , 2020, 10, 329-338.	3.0	1
88	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. <i>Current Dermatology Reports</i> , 2021, 10, 6-15.	2.1	1
89	Inpatient Management of Psoriasis: A Current Perspective and Update for Clinicians. <i>Current Dermatology Reports</i> , 2021, 10, 205-221.	2.1	1
90	A cross-sectional study of ethnoracial representation in pediatric plaque psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 442-444.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Improvement in Quality of Life in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Ustekinumab. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 161-166.	0.7	0
92	Article Commentary: Explaining the Shift to Value-Based Reimbursement in the Setting of Dermatology and Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2016, 2, 5-8.	0.7	0
93	Chronic erythema nodosum with koebnerization to plaque psoriasis. International Journal of Women's Dermatology, 2019, 5, 387-388.	2.0	0
94	Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. Dermatology and Therapy, 2020, 10, 107-117.	3.0	0
95	<p>Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults</p>. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 391-398.	1.8	0
96	Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis. Current Dermatology Reports, 2021, 10, 21-25.	2.1	0
97	A common treatment for a rare condition: Narrowbandâ€Ultraviolet B (NBâ€UVB) phototherapy for the treatment of a recalcitrant acquired port wine stain. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 293-295.	1.5	0
98	The future of personalized medicine in psoriasis. Dermatological Reviews, 2021, 2, 282.	0.5	0
99	Biologics update: ILâ€23 inhibitors. Dermatological Reviews, 2021, 2, 276.	0.5	0
100	Atypical Presentation of Pityriasis Rubra Pilaris: Challenges in Diagnosis and Management. , 2021, 108, E33-E35.		0